Literature DB >> 25284254

Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol.

Alberto Fernández-Tejada1, Eric K Chea2, Constantine George3, Jeffrey R Gardner4, Philip O Livingston3, Govind Ragupathi5, Derek S Tan6, David Y Gin7.   

Abstract

Immunoadjuvants are used to potentiate the activity of modern subunit vaccines that are based on molecular antigens. An emerging approach involves the combination of multiple adjuvants in a single formulation to achieve optimal vaccine efficacy. Herein, to investigate such potential synergies, we synthesized novel adjuvant conjugates based on the saponin natural product QS-21 and the aldehyde tucaresol via chemoselective acylation of an amine at the terminus of the acyl chain domain in QS saponin variants. In a preclinical mouse vaccination model, these QS saponin-tucaresol conjugates induced antibody responses similar to or slightly higher than those generated with related QS saponin variants lacking the tucaresol motif. The conjugates retained potent adjuvant activity, low toxicity, and improved activity-toxicity profiles relative to QS-21 itself and induced IgG subclass profiles similar to those of QS-21, indicative of both Th1 cellular and Th2 humoral immune responses. This study opens the door to installation of other substituents at the terminus of the acyl chain domain to develop additional QS saponin conjugates with desirable immunologic properties.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Carbohydrates; Immunoadjuvant; Natural product; QS-21; Saponin conjugate; Tucaresol; Vaccine

Mesh:

Substances:

Year:  2014        PMID: 25284254      PMCID: PMC4410046          DOI: 10.1016/j.bmc.2014.09.016

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  36 in total

1.  Marked enhancement of the antigen-specific immune response by combining plasmid DNA-based immunization with a Schiff base-forming drug.

Authors:  Jehad Charo; Maria Sundbäck; Ken Wasserman; Anne-Marie T Ciupitu; Babak Mirzai; Ruurd van der Zee; Rolf Kiessling
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

Review 2.  Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity.

Authors:  Dante J Marciani
Journal:  Drug Discov Today       Date:  2003-10-15       Impact factor: 7.851

3.  First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.

Authors:  Selidji Todagbe Agnandji; Bertrand Lell; Solange Solmeheim Soulanoudjingar; José Francisco Fernandes; Béatrice Peggy Abossolo; Cornelia Conzelmann; Barbara Gaelle Nfono Ondo Methogo; Yannick Doucka; Arnaud Flamen; Benjamin Mordmüller; Saadou Issifou; Peter Gottfried Kremsner; Jahit Sacarlal; Pedro Aide; Miguel Lanaspa; John J Aponte; Arlindo Nhamuave; Diana Quelhas; Quique Bassat; Sofia Mandjate; Eusébio Macete; Pedro Alonso; Salim Abdulla; Nahya Salim; Omar Juma; Mwanajaa Shomari; Kafuruki Shubis; Francisca Machera; Ali Said Hamad; Rose Minja; Ali Mtoro; Alma Sykes; Saumu Ahmed; Alwisa Martin Urassa; Ali Mohammed Ali; Grace Mwangoka; Marcel Tanner; Halidou Tinto; Umberto D'Alessandro; Hermann Sorgho; Innocent Valea; Marc Christian Tahita; William Kaboré; Sayouba Ouédraogo; Yara Sandrine; Robert Tinga Guiguemdé; Jean Bosco Ouédraogo; Mary J Hamel; Simon Kariuki; Chris Odero; Martina Oneko; Kephas Otieno; Norbert Awino; Jackton Omoto; John Williamson; Vincent Muturi-Kioi; Kayla F Laserson; Laurence Slutsker; Walter Otieno; Lucas Otieno; Otsyula Nekoye; Stacey Gondi; Allan Otieno; Bernhards Ogutu; Ruth Wasuna; Victorine Owira; David Jones; Agnes Akoth Onyango; Patricia Njuguna; Roma Chilengi; Pauline Akoo; Christine Kerubo; Jesse Gitaka; Charity Maingi; Trudie Lang; Ally Olotu; Benjamin Tsofa; Philip Bejon; Norbert Peshu; Kevin Marsh; Seth Owusu-Agyei; Kwaku Poku Asante; Kingsley Osei-Kwakye; Owusu Boahen; Samuel Ayamba; Kingsley Kayan; Ruth Owusu-Ofori; David Dosoo; Isaac Asante; George Adjei; George Adjei; Daniel Chandramohan; Brian Greenwood; John Lusingu; Samwel Gesase; Anangisye Malabeja; Omari Abdul; Hassan Kilavo; Coline Mahende; Edwin Liheluka; Martha Lemnge; Thor Theander; Chris Drakeley; Daniel Ansong; Tsiri Agbenyega; Samuel Adjei; Harry Owusu Boateng; Theresa Rettig; John Bawa; Justice Sylverken; David Sambian; Alex Agyekum; Larko Owusu; Francis Martinson; Irving Hoffman; Tisungane Mvalo; Portia Kamthunzi; Ruthendo Nkomo; Albans Msika; Allan Jumbe; Nelecy Chome; Dalitso Nyakuipa; Joseph Chintedza; W Ripley Ballou; Myriam Bruls; Joe Cohen; Yolanda Guerra; Erik Jongert; Didier Lapierre; Amanda Leach; Marc Lievens; Opokua Ofori-Anyinam; Johan Vekemans; Terrell Carter; Didier Leboulleux; Christian Loucq; Afiya Radford; Barbara Savarese; David Schellenberg; Marla Sillman; Preeti Vansadia
Journal:  N Engl J Med       Date:  2011-10-18       Impact factor: 91.245

4.  Divergent immunoglobulin g subclass activity through selective Fc receptor binding.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2005-12-02       Impact factor: 47.728

Review 5.  Schiff base forming drugs: mechanisms of immune potentiation and therapeutic potential.

Authors:  H Chen; J Rhodes
Journal:  J Mol Med (Berl)       Date:  1996-09       Impact factor: 4.599

6.  An essential role for constitutive Schiff base-forming ligands in antigen presentation to murine T cell clones.

Authors:  X M Gao; J Rhodes
Journal:  J Immunol       Date:  1990-04-15       Impact factor: 5.422

7.  Erythrocyte rosettes provide an analogue for Schiff base formation in specific T cell activation.

Authors:  J Rhodes
Journal:  J Immunol       Date:  1990-07-15       Impact factor: 5.422

Review 8.  Vaccine adjuvants: putting innate immunity to work.

Authors:  Robert L Coffman; Alan Sher; Robert A Seder
Journal:  Immunity       Date:  2010-10-29       Impact factor: 31.745

Review 9.  Accelerating next-generation vaccine development for global disease prevention.

Authors:  Wayne C Koff; Dennis R Burton; Philip R Johnson; Bruce D Walker; Charles R King; Gary J Nabel; Rafi Ahmed; Maharaj K Bhan; Stanley A Plotkin
Journal:  Science       Date:  2013-05-31       Impact factor: 47.728

Review 10.  GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.

Authors:  Nathalie Garçon; Patrick Chomez; Marcelle Van Mechelen
Journal:  Expert Rev Vaccines       Date:  2007-10       Impact factor: 5.217

View more
  6 in total

1.  Synthesis and Evaluation of QS-7-Based Vaccine Adjuvants.

Authors:  Pengfei Wang; Đani Škalamera; Xianwei Sui; Ping Zhang; Suzanne M Michalek
Journal:  ACS Infect Dis       Date:  2019-03-28       Impact factor: 5.084

2.  Novel Oxime-Derivatized Synthetic Triterpene Glycosides as Potent Saponin Vaccine Adjuvants.

Authors:  Roberto Fuentes; Leire Aguinagalde; Carlo Pifferi; Adrián Plata; Nagore Sacristán; Donatello Castellana; Juan Anguita; Alberto Fernández-Tejada
Journal:  Front Immunol       Date:  2022-05-06       Impact factor: 8.786

3.  Semisynthesis of Analogues of the Saponin Immunoadjuvant QS-21.

Authors:  Alberto Fernández-Tejada; William E Walkowicz; Derek S Tan; David Y Gin
Journal:  Methods Mol Biol       Date:  2017

4.  Synthesis, Formulation, and Adjuvanticity of Monodesmosidic Saponins with Olenanolic Acid, Hederagenin and Gypsogenin Aglycones, and some C-28 Ester Derivatives.

Authors:  Ben W Greatrex; Alison M Daines; Sarah Hook; Dirk H Lenz; Warren McBurney; Thomas Rades; Phillip M Rendle
Journal:  ChemistryOpen       Date:  2015-09-30       Impact factor: 2.911

5.  Design, synthesis, and initial immunological evaluation of glycoconjugates based on saponin adjuvants and the Tn antigen.

Authors:  Roberto Fuentes; Leire Aguinagalde; Nagore Sacristán; Alberto Fernández-Tejada
Journal:  Chem Commun (Camb)       Date:  2021-10-28       Impact factor: 6.222

6.  Development of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical Synthesis.

Authors:  Alberto Fernández-Tejada; Derek S Tan; David Y Gin
Journal:  Acc Chem Res       Date:  2016-08-28       Impact factor: 22.384

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.